Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
MIMEDX (Nasdaq: MDXG) announced that senior management will participate in the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28, 2026, in Minneapolis, MN.
Interested investors are invited to request meetings with management through their Craig-Hallum representative.
MiMedx (Nasdaq: MDXG) announced the commercial launch of G4Derm Plus on May 8, 2026, with initial U.S. sales already delivered and exclusive U.S. distribution rights secured.
G4Derm Plus is a 510(k)-cleared, acellular flowable extracellular matrix using self-assembling peptide technology. The product supports revascularization, granulation, and re-epithelialization and serves as an antibacterial barrier. The product is available through Premier and Vizient GPO agreements for national hospital access.
MIMEDX (Nasdaq: MDXG) reported Q1 2026 net sales of $59 million, down 33% year-over-year, driven by a 60% decline in Wound sales while Surgical sales rose 13%.
The company cut 2026 net sales guidance to $260–$290 million and now expects ~breakeven Adjusted EBITDA for 2026; cash was $160 million at March 31, 2026.
MiMedx (Nasdaq: MDXG) will report first quarter 2026 operating and financial results for the period ended March 31, 2026, after market close on Wednesday, April 29, 2026. The senior management team will host a webcast and conference call beginning at 4:30 p.m. Eastern Time that day.
According to the company, U.S. and international dial‑in numbers and a conference ID are provided, and a replay will be available on the company website for approximately 30 days following the event.
MiMedx (Nasdaq: MDXG) announced a restructuring to reduce annual operating expenses by approximately $40 million and expects a one-time $4 million restructuring charge in Q2 2026. The company eliminated the Chief Operating Officer role and plans additional commentary with Q1 2026 results in late April.
Management said Surgical will receive further investment while Wound Care is recovering slowly after the January 1 Medicare reimbursement reduction.
MiMedx Group (Nasdaq: MDXG) will sponsor and present at two leading wound care conferences: SAWC Spring 2026 (April 8–12, Charlotte) and DLS 2026 (April 8–11, Washington, D.C.).
Activities include sponsored symposia, multiple poster and oral clinical presentations, and exhibit booths to showcase peptide-based and placental allograft wound-care technologies.
MiMedx (Nasdaq: MDXG) announced the commercial launch of CHORIOFIX on March 23, 2026, a lyophilized placental allograft composed of two chorion layers with an intact intermediate layer.
The company said CHORIOFIX is its thickest product to date, designed to improve handling, positioning and suturing, and has been added to the prospective randomized CAMPAIGN trial to evaluate performance versus standard of care in non-healing diabetic foot ulcers.
MiMedx (Nasdaq: MDXG) launched AMNIOFIX Thyroid Shields, a DHACM allograft line for endocrine surgery designed to protect the recurrent laryngeal nerve and parathyroid glands after thyroidectomy.
The product is preconfigured for operating-room use, shelf-stable up to five years, manufactured with the PURION process, and supported by a retrospective single-center study showing a 76% reduction in 24-hour RLN damage (3.4% vs 14.4%, p<0.01).
MIMEDX (Nasdaq: MDXG) reported record 2025 results with Q4 net sales $118M (+27% YoY) and full-year net sales $419M (+20% YoY). Q4 GAAP net income was $15M and full-year net income was $49M. Adjusted EBITDA for Q4 was $29M (25% of net sales). Cash totaled $166M at year-end. The board authorized a $100M share repurchase over two years. For 2026 the company estimates net sales of $340–360M and adjusted EBITDA margin in the mid-to-high teens.
MiMedx (Nasdaq: MDXG) will report fourth quarter and full year 2025 operating and financial results after market close on Wednesday, February 25, 2026.
The senior management team will host a webcast and conference call beginning at 4:30 p.m. ET on February 25. A replay will be available on the company website for approximately 30 days.